Activity of novobiocin against methicillin-resistantStaphylococcusaureus

Publisher Website
Google Scholar
Abstract
As infections due to methicillin-resistantStaphylococcus aureus become increasingly prevalent, newer alternative antibiotics, especially those which are orally administered, will be required. In order to provide anm-vitro basis for selecting alternative antibiotics, we studied the susceptibility of 103 strains of methicillin-resistantStaph aureus from seven institutions to oral antimicrobial agents. Novobiocin, nfampicin, and tnmethoprim-sulphamethoxazole had excellentin-vitro activity against virtually all strains of methicillin-resistantStaph aureus. The MIC90 and MBC90 of novobiocin against methicillin-resistantStaph aureus were 0–25 mg/1. Since previously reported achievable serum levels with oral novobiocin are 100 to 200 times its MIC90 against methicillin-resistant Staph. aureus, novobiocin should be evaluated further for combination therapy with nfampicin or trimethopnm-sulphamethoxazole.